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Background: Annexin A1 (ANXA1), a 37 kDa multifunctional protein, is over-expressed in tissues from patients
of pancreatic carcinoma (PC) where the protein seems to be associated with malignant transformation and
poor prognosis.
Methods: The expression and localization of ANXA1 in MIA PaCa-2, PANC-1, BxPC-3 and CAPAN-2 cells were
detected by Western Blotting and Immunofluorescence assay. Expression and activation of Formyl Peptide Receptors
(FPRs) were shown through flow cytometry/PCR and FURA assay, respectively. To investigate the role of ANXA1 in PC
cell migration and invasion, we performed in vitro wound-healing and matrigel invasion assays.
Results: In all the analyzed PC cell lines, a huge expression and a variable localization of ANXA1 in sub-cellular
compartments were observed. We confirmed the less aggressive phenotype of BxPC-3 and CAPAN-2 compared
with PANC-1 and MIA PaCa-2 cells, through the evaluation of Epithelial-Mesenchymal Transition (EMT) markers.
Then, we tested MIA PaCa-2 and PANC-1 cell migration and invasiveness rate which was inhibited by specific ANXA1
siRNAs. Both the cell lines expressed FPR-1 and -2. Ac2-26, an ANXA1 mimetic peptide, induced intracellular calcium
release, consistent with FPR activation, and significantly increased cell migration/invasion rate. Interestingly, in MIA
PaCa-2 cells we found a cleaved form of ANXA1 (33 kDa) that localizes at cellular membranes and is secreted outside
the cells, as confirmed by MS analysis. The importance of the secreted form of ANXA1 in cellular motility was confirmed
by the administration of ANXA1 blocking antibody that inhibited migration and invasion rate in MIA PaCa-2 but not in
PANC-1 cells that lack the 33 kDa ANXA1 form and show a lower degree of invasiveness. Finally, the treatment of
PANC-1 cells with MIA PaCa-2 supernatants significantly increased the migration rate of these cells.
Conclusion: This study provides new insights on the role of ANXA1 protein in PC progression. Our findings suggest
that ANXA1 protein could regulate metastasis by favouring cell migration/invasion intracellularly, as cytoskeleton
remodelling factor, and extracellularly like FPR ligand.
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Pancreatic carcinoma (PC) is one of the most aggressive
gastrointestinal malignancies worldwide, with poor prog-
nosis [1] and a 5-year survival rate of 3-5% [2].
The current standard treatment for patients affected
by PC is surgery, radiations and drugs as gemcitabine
and TS-1 [3]. However, most patients present a marked* Correspondence: apetrella@unisa.it
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unless otherwise stated.resistance to chemo- and radiotherapy that impacts their
therapeutic effects. Moreover, PC invades progressively
and metastasizes to liver and lymph nodes during early
stages without remarkable symptoms so that, surgery is
not an option for the majority of these patients that
present rapid relapse [4,5].
Tumour metastases are the most common causes of
death in cancer patients and represent the utmost challenge
for cancer treatment. In particular cell migration and inva-
sion play a crucial role in the progression of cancer sinceral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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better understanding of the mechanisms underlying these
processes is important for the development of novel anti-
cancer agents in order to improve clinical outcome.
Annexin A1 (ANXA1) is a key member of the A sub-
family and belongs to the multi-gene family of annexins.
ANXA1 exhibits calcium-mediated phospholipid binding
properties and participates in many physiopathological
processes, including inhibition of cell proliferation, anti-
inflammatory effects, regulation of cell migration, differ-
entiation and death [7].
ANXA1 appearance is in a tissue- and tumour-specific
manner and its anomalous expression is closely related
to cancer progression [8,9]. Up-regulated ANXA1 expres-
sion was correlated with tumour progression in urothelial
carcinoma, glioma, colon carcinoma and lung squamous
carcinoma, whereas down-regulated ANXA1 expression
was observed in prostate, oral and gastric cancer progres-
sion. This suggests that ANXA1 influences cancer pro-
gression in different ways and that it may have different
sub-cellular localizations that determine its functions [10].
One of this ways could be due to ANXA1 well known
ability to bind F-actin in a Ca2+-dependent manner since
the protein has been found to accumulate concomitantly
with the appearance of F-actin at the ruffles and at the
cell-cell contacts in several biological systems [11]. How-
ever, the relevance and the significance of this property
remain unclear to date, also in cancer cells where the
motility is driven by reorganization of the cytoskeleton
and of the contacts between the cell and the matrix.
ANXA1 has been shown to localize to the cell surface
of various cell types where it is thought to be important
in biological functions as myoblast and skin fibroblast
migration and cytoskeleton reorganization [12,13]. The
extracellular form of ANXA1 has been as well described
to play a role in cancer cell invasion and metastasis. The
most significant example is breast cancer, where the
pro-invasive effect of ANXA1 is triggered by the inter-
action with the Formyl Peptide Receptors (FPRs) [14].
The regulatory action on cell surface by extracellular
ANXA1 is indeed thought to be mediated by signalling
through FPRs [12,13,15]. FPRs are G-protein coupled
chemoattractant receptors, which can sense gradients of
bacterial peptides such as formyl-Methionine-Leucine-
Phenylalanine (fMLP) and thereby direct leukocytes
towards sites of bacterial infection [16]. Three human
FPR family members have been identified including
FPR-1, FPR-2, and FPR-3. Ligand binding to FPR activates
a number of downstream effector enzymes including
phospholipase C, catalyzing the cleavage of phosphatidyl
inositol 4,5-biphosphate into secondary messengers in-
ositol 1,4,5-triphosphate and diacylglycerol leading to
calcium mobilization and activation of protein kinase C
(PKC) [16-18].Previous studies have shown that tumour cells from
highly malignant human glioma specimens express FPR-
1 [19]; subsequently it has been shown that ANXA1
released by necrotic human glioblastoma cells was able
to stimulate tumour cell growth through FPR-1 [20].
Interestingly, it has also been shown that the transloca-
tion of ANXA1 to the cell surface is partially responsible
for promoting cell migration and invasion in colorectal
carcinoma cell line SKCO-15, indicating an autocrine/
paracrine role for membrane ANXA1 [21].
Despite the identification of ANXA1 as one of the several
proteins that is differentially expressed during the progres-
sion of tumours to more malignant states, a functional role
for ANXA1 in PC advancing is lacking. The aim of our
study is to investigate the role of ANXA1 in human PC
progression, in particular we focused on its involvement in
cancer cell migration and invasiveness.
Methods
Cell cultures
MIA PaCa-2, human PC cells, were cultured in DMEM
(Lonza) containing L-Glutamine 2 mM, 10% heat-
inactivated fetal bovine serum (FBS; Lonza) and 2,5%
heat inactivated horse serum (HS; Lonza). PANC-1, hu-
man pancreatic epithelioid carcinoma cells, were kept in
DMEM containing L-Glutamine 2 mM and 10% heat-
inactivated fetal bovine serum (FBS; Lonza). BxPC-3,
human pancreatic adenocarcinoma cells, were cultured
in RPMI 1640 (Lonza) containing 10% heat-inactivated
fetal bovine serum (FBS; Lonza). CAPAN-2, human
PDAC cells, were kept in McCoy’s 5a Medium Modified
(Lonza) with 10% heat-inactivated fetal bovine serum
(FBS; Lonza). All the media were supplemented with
antibiotics (10000 U/ml penicillin and 10 mg/ml strepto-
mycin; Lonza). Cell lines were purchased from ATCC
(Rockville, USA) and were grown at 37°C in 5% CO2 -95%
air humidified atmosphere.
Cytosol and membrane extracts
MIA PaCa-2 and PANC-1 cells were washed twice with
PBS, detached with trypsin-EDTA 1× in PBS (Euroclone),
harvested in PBS and centrifuged for 5 minutes at 600 × g
at 4°C. After that, the pellets were resuspended in 4 ml of
lysis buffer (Tris HCl 20 mM, pH 7,4; sucrose 250 mM;
DTT 1 mM; protease inhibitors, EDTA 1 mM in water),
sonicated (5 seconds pulse - 9 seconds pause for 2 mi-
nutes, amplitude 42%) and then centrifuged at 4°C for
10 minutes, at 5000 × g. The obtained supernatants were
ultra-centrifuged for 1 hour at 100000 × g at 4°C, until to
get new supernatants that represent cytosol extracts. Each
resulting pellet was resuspended in 4 ml of lysis buffer and
ultra-centrifuged for 1 hour at 100000 × g at 4°C. The
pellets were then resuspended in 250 μl of solubilization
buffer (Tris HCl 20 mM, pH 7,4; DTT 1 mM; EDTA
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orbital shaker at 4°C. After that, the solution was centri-
fuged for 30 minutes at 50000 × g at 4°C: the supernatants
represent membrane extracts. To detect membrane ex-
pression of ANXA1 we also use an EDTA Wash method,
as previously described [22].
Nuclear extracts
MIA PaCa-2 and PANC-1 cells were washed twice with
PBS, detached with trypsin-EDTA 1× in PBS (Euroclone),
harvested in PBS and centrifuged for 5 minutes at 600 × g
at 4°C. The pellets were resuspended in 500 μl of buffer A
(Hepes pH 7.9 10 mM, EDTA pH 8.0 1 mM, KCl 60 mM,
N-P40 0.2%, DTT 1 mM, PMSF 1 mM, protease inhibi-
tors) and then left on ice for 10 minutes. After that, the
samples were centrifuged at 660 × g for 5 minutes at 4°C,
resuspended in 50 μl of buffer B (Tris HCl pH 7.8
250 mM, KCl 60 mM, DTT 1 mM, PMSF 2 mM, glycerol
20% v/v in PBS) and centrifuged again at 9500 × g for
15 minutes at 4°C. The obtained pellets were resuspended
in 100 μl of buffer C (Hepes pH 7.9 10 mM, EDTA pH 8.0
1 mM, KCl 60 mM, DTT 1 mM, PMSF 1 mM, protease
inhibitors) and centrifuged at 660 × g for 5 minutes at
4°C. The samples were then washed twice with 1 ml of
buffer C, resuspended in 50 μl of buffer B and exposed
to 3 cycles of freeze/thawing. Finally, the samples were
centrifuged at 9500 × g for 15 minutes at 4°C: the pellets
represent the nuclear extracts.
Supernatant analysis
Cell growth media were harvested, frozen at -80°C and
lyophilized. Dried samples were suspended in lysis
buffer containing protease inhibitors and left at 4°C for
30 minutes. After centrifugation, the supernatants were
filtered through Amicon Ultra-15, PLTK Ultracel-PL
Membrane, 10 kDa (Millipore). The filtrates were loaded
on a Chromabond HR-X micro-column (Macherey-Nagel)
and eluted with 70% ACN and 95% ACN. Eluted samples
were analyzed by LC/MS/MS using an Orbitrap XL in-
strument (Thermo Scientific) as reported elsewhere [23].
Western blotting analysis
Expression of ANXA1 was examined by SDS-PAGE. Total
intracellular proteins were extracted from the cells by
freeze/thawing in lysis buffer containing protease inhibitors.
Protein content was estimated according to Biorad protein
assay (BIO-RAD). Samples (20 μg protein) were loaded
onto 10% denaturing-polyacrylamide gel and separated by
SDS-PAGE. The separated proteins were then transferred
electrophoretically to nitrocellulose membranes (Immobi-
lon-NC, Millipore). Membranes were blocked with 5%
non-fat dry milk in TBS-Tween 20 (0.1% v/v) and then
incubated overnight at 4°C with the primary antibodies.
Proteins were visualized using the enhanced chemiolumi-nescence detection system (Amersham Pharmacia Bio-
tech) after incubation overnight at 4°C with primary poly-
clonal antibody against ANXA1 (1:10000; Invitrogen) and
monoclonal a-tubulin (1:1000; Sigma-Aldrich) and then at
RT with an appropriate secondary rabbit or mouse anti-
body (1:5000; Sigma-Aldrich). Immunoreactive protein
bands were detected by chemioluminescence using en-
hanced chemioluminescence reagents (ECL; Amersham),
the blots were exposed and analyzed to Las4000 (GE
Healthcare Life Sciences).
siRNA transfection
The 4, 6, 7 and 8 siRNA sequences against ANXA1 were
purchased from Qiagen and used at a final concentration
of 5 nM. siRNA Oligo-Scrambled (Santa Cruz Biotech-
nology) was used as control at the same concentration.
siRNAs were transfected using Lipofectamine 2000 Re-
agent (Life technologies Corporation), according to the
manufacturer′s instructions. Cells were harvested after
72 hours from transfection.
Confocal microscopy
After the specific time of incubation, MIA PaCa-2,
PANC-1, BxPC-3 and CAPAN-2 cells were fixed in p-
formaldehyde (4% v/v in PBS) for 5 minutes. The cells
were permeabilized in Triton X-100 (0.5% v/v in PBS) for
5 minutes, and then incubated in goat serum (20% v/v
PBS) for 30 minutes, and with rabbit anti-ANXA1 anti-
body (1:100; Invitrogen), mouse anti-FAK (1:100; BD
Transduction Laboratories), mouse anti-E-cadherin (1:250;
Santa Cruz Biotechnology) and/or mouse anti-vimentin
(1:500; Santa Cruz Biotechnology) overnight at 4°C. After
two washing steps with PBS, cells were incubated with
anti-rabbit and/or anti-mouse AlexaFluor (488 and/or 555;
1:1000; Molecular Probes) for 2 hours at RT and then with
FITC-conjugated anti-F-actin (5 μg/ml; Phalloidin-FITC,
Sigma) for 30 minutes at RT in the dark. The coverslips
were mounted in glycerol (40% v/v PBS). A Zeiss LSM 710
Laser Scanning Microscope (Carl Zeiss MicroImaging
GmbH) was used for data acquisition. To detect nucleus,
samples were excited with a 458 nm Ar laser. A 555 nm
He-Ne laser was used to detect emission signals from
ANXA1 stain. Samples were vertically scanned from the
bottom of the coverslip with a total depth of 5 mm and a
63× (1.40 NA) Plan-Apochromat oil-immersion objective.
Images were generated with Zeiss ZEN Confocal Software
(Carl Zeiss MicroImaging GmbH).
Flow cytometry
MIA PaCa-2 and PANC-1 cells were harvested at a number
of 1 × 106 and centrifuged at 30000 × g for 5 minutes. The
pellets were then incubated on ice for 1 hour in 100 μl
of PBS containing a primary polyclonal antibody against
FPR-1 (1:500, Santa Cruz Biotechnology) or a primary
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After that, MIA PaCa-2 and PANC-1 cells were washed
twice and incubated on ice for 1 hour in 100 μl of PBS
containing AlexaFluor 488 anti-rabbit (1:1000; Molecular
Probes) or AlexaFluor 488 anti-mouse (1:1000; Molecular
Probes). The cells were analyzed with Becton Dickinson
FACScan flow cytometer using the Cells Quest program.
PCR
MIA PaCa-2 and PANC-1 cells were seeded at an initial
density of 1 × 106 in a 100 mm Petri dish and incubated
for 48 hours in growth medium allowing cells to reach
90% confluency. Total RNA was extracted from cells using
Trizol (Invitrogen) [24]. Total RNA (5 μg) was used to
synthesize cDNA using a reverse transcription kit (Roche).
PCR was conducted by using the following primers:
FPR-1 primer pair: (fwd 5’-CAA GAT GGA GAC AAA
TTC CTC TC-3’) and (rev 3’-GAG CAG AGC CAT
CAC CCA GGG CCC AA-5’);
FPR-2 primer pair: (fwd 5’-CTG TAC TTT CAA CTT
TGC ATC C-3’) and (rev 3’-ATT TCC CAA CTC
CAC TTA CC-5’);
The predicted FPR-1 and FPR-2 products are 469 bp
and 773 bp, respectively. The FPR-1 and FPR-2 genes were
amplified using PCR under the following conditions:
pre-denaturation at 94°C for 2 minutes, 35 cycles of
denaturation at 94°C for 30 seconds, annealing at 60°C
for 30 seconds, extension at 72°C for 30 seconds and a
final extension at 72°C for 10 minutes. The products
were stored at 4°C. A portion (5 μl) of the PCR product
was electrophoresed on a 1% agarose gel in a Tris-acetate-
EDTA buffer. The gel was stained with ethidium bromide
and was scanned and analysed to Las4000 (GE Healthcare
Life Sciences).
Measurement of intracellular Ca2+ signalling
Intracellular Ca2+ concentrations [Ca2+] were measured
using the fluorescent indicator dye Fura 2-AM, the
membrane-permeant acetoxymethyl ester form of Fura
2, as previously described [25], with minor revisions.
Briefly, MIA PaCa-2 and PANC-1 cells (5 × 103/multiwell
24 culture dishes) were washed in PBS and re-suspended
in 1 ml of Hank’s balanced salt solution (HBSS) containing
5 μM Fura 2-AM for 45 minutes. Thereafter, cells were
washed with the same buffer to remove excess of Fura 2-
AM and incubated in Ca2+-free HBSS/0.5 mM EGTA
buffer for 15 minutes to allow hydrolysis of Fura 2-AM
into its active-dye form, Fura 2. MIA PaCa-2 and PANC-1
cells were then transferred to the spectrofluorimeter
(Perkin-Elmer LS-55). Treatment with ionomycin (1 μM),
fMLP (50 nM, Sigma Aldrich), with Ac 2-26 (1 μM, Tocris
Bioscience) or Boc-1 (10 μM, Bachem AG) was carriedout by adding the appropriate concentrations of each sub-
stance into the cuvette in Ca2+-free HBSS/0.5 mM EGTA
buffer. The excitation wavelength was alternated between
340 and 380 nm, and emission fluorescence was recorded
at 515 nm. The ratio of fluorescence intensity of 340/
380 nm (F340/F380) was used to estimate intracellular
free calcium. Results are indicated as delta increase of
fluorescence ratio (F340/F380 nm) induced by ionomy-
cin - basal fluorescence ratio (F340/F380 nm).
In vitro wound-healing assay
MIA PaCa-2 and PANC-1 cells were seeded in a 12-well
plastic plate at 5 × 105 cells per well. After 24 hours
incubation, cells reached 100% confluency and a wound
was produced at the centre of the monolayer by gently
scraping the cells with a sterile plastic p10 pipette tip.
After removing incubation medium and washing with
PBS, cell cultures were incubated in the presence of
fMLP (50 nM), Ac2-26 (1 μM), Boc-1 (10 μM) or in
growth medium as control. In case of transfection with
siANXA1s, cells were plated at a number of 2 × 105,
after 24 hours were transfected with siANXA1s or with
scrambled siRNAs and, 72 hours after transfection,
wound was produced. The wounded cell cultures were
then incubated at 37°C in a humidified and equilibrated
(5% v/v CO2) incubation chamber of an Integrated Live
Cell Workstation Leica AF-6000 LX. A 10× phase con-
trast objective was used to record cell movements with a
frequency of acquisition of 10 minutes. The migration
rate of individual cells was determined by measuring the
distances covered from the initial time to the selected
time-points (bar of distance tool, Leica ASF software).
For each condition five independent experiments were
performed. For each wound five different positions were
registered, and for each position ten different cells were
randomly selected to measure the migration distances.
Statistical analysis was performed by using GraphPad
Prism software (GraphPad Software Inc., version 5.0).
Data are presented as means ± SEM. Values p < 0.05 were
considered as significant.
Matrigel invasion assay
MIA PaCa-2 and PANC-1 invasiveness was studied
using the Trans-well Cell Culture (12 mm diameter, 8.0-
fim pore size) purchased form Corning Incorporated
(USA). The chambers were coated with Matrigel (Becton
Dickinson Labware) that was diluted with 3 volumes of
DMEM serum-free and stored at 37°C until its gelation.
Cells were plated in 350 μl of DMEM serum-free at a
number of 9 × 104/insert in the upper chamber of the
trans-well. 1,4 ml of DMEM with or without FBS were
put in the lower chamber and the trans-well was left for
24 hours at 37°C in 5% CO2 -95% air humidified atmos-
phere. After that, the medium was aspirated, the filters
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formaldehyde for 10 minutes, then with 100% methanol
for 20 minutes. The filters so fixed, were stained with
0,5% crystal violet prepared from stock crystal violet
(powder, Merck Chemicals) by distilled water and 20%
methanol for 15 minutes. After that, the filters were
washed again in PBS 1× and cleaned with a cotton bud.
The number of cells that had migrated to the lower sur-
face was counted in twelve random fields using EVOS
light microscope (10×) (Life technologies Corporation).
Statistical analysis
All results are the mean ± SEM of at least 3 experiments
performed in triplicate. The optical density of the pro-
tein bands detected by Western blotting was normalized
against tubulin levels. Statistical comparisons between
groups were made using two-way ANOVA or unpaired,
two-tailed t-test comparing two variables. Differences
were considered significant if p < 0.05 and p < 0.01.
Results
Expression and localization of ANXA1 in PC cell lines
ANXA1 role in PC progression is poorly described.
Therefore, we initially focused to define how ANXA1 is
expressed and localized in several human PC cell lines
as MIA PaCa-2, PANC-1, BxPC-3 and CAPAN-2. These
cells show many differences about their genotype, such
as Kras or p16 mutations, and phenotype, as adhesion,
migration, invasion and angiogenesis capacities [26]. As
shown in Figure 1A, Western blotting analyses revealed
that all cell lines expressed ANXA1.
Next, we characterized MIA PaCa-2, PANC-1, BxPC3
and CAPAN-2 cells on the basis of their phenotype since
the more aggressive and invasive cancer cells had a
higher basal Epithelial-Mesenchymal Transition (EMT)
signature [27]. Confocal microscopy analyses confirmed,
as previously described [26], more aggressive features for
MIA PaCa-2 and PANC-1 as, differently from BxPC-3 and
CAPAN-2, these cancer cells possess a marked mesenchy-
mal phenotype characterized by up-regulation of the
mesenchymal marker vimentin and down-regulation of
the epithelial marker E-cadherin (Figure 1B,C,D) [28].
Tumour cell invasion and metastasis processes involve
many proteins that are required for normal cell motility.
As it is known that ANXA1 plays a role in normal cell
migration [12,13] and in cancer cell invasion and metas-
tasis [14,10], we also analyzed by confocal microscopy
ANXA1 localization in the cellular motility structures
identified by using focal adhesion kinase (FAK) or F-
actin staining. In the figure 1E (panels c, f ) we show that
ANXA1 co-localized in both MIA PaCa-2 and PANC-1
cells with FAK, a protein commonly expressed in adhe-
sion hot spots of migrating/invasive cells. Moreover, we
show an actin-like filamentous ANXA1 organization andan enrichment of the protein at burble ends and extrusions
in MIA PaCa-2 cells (Figure 1E, panel i). Also in PANC-1
cells ANXA1 co-localized with F-actin protein although
this cell line is characterized by a less mesenchymal-like
phenotype (Figure 1E, panel n).
Effects of ANXA1 knockdown on MIA PaCa-2 and PANC-1
cell migration and invasiveness
As it is known from previous reports and confirmed by
our data using confocal microscopy, PANC-1 and MIA
PaCa-2, differentially from CAPAN-2 and BxPC-3, show
a more aggressive phenotype, particularly MIA PaCa-2
that have an higher tumorigenic potential [29,26].
We observed that in MIA PaCa-2 and PANC-1 cell
lines ANXA1 localized in the regions that are involved in
the cell movement. As the migration/invasion processes
start once cells form actin- and FAK-rich protrusions that
adhere to the matrix and create the tension forces neces-
sary for cell motility [30], we hypothesised a role for the
protein in these processes. The expression of ANXA1 was
greatly reduced in MIA PaCa-2 (Figure 2A) and PANC-1
(Figure 2D) cells by specific siRNA transfection. Thus a
wound-healing migration assay on cellular monolayer in
ANXA1 knockdown cells was performed. The confluent
cultures were scraped to create a wound and cell migra-
tion was monitored by time-lapse video-microscopy at the
site of the wound. We measured the migration distances
of selected cells at different time points as described in
Methods section. In ANXA1 knockdown MIA PaCa-2
(Figure 2B) and PANC-1 (Figure 2E) cells the rate of
migration decreased in a significant manner, if compared
with the wild type control and with scrambled RNA trans-
fected cells.
The matrigel invasion assay was also performed in
ANXA1 knockdown MIA PaCa-2 and PANC-1 cells to
investigate the role of ANXA1 on their invasion ability.
As shown in Figure 2C and 2F, siRNAs against ANXA1
markedly suppressed the invasiveness of both PC cell
lines. To confirm the technical efficiency of our experi-
ment, we used a serum free control to eliminate any
chemoattractant condition: in this way we found signifi-
cantly less invading cells on the lower surface of matrigel
(data not shown).
Localization and cleavage of endogenous ANXA1 in MIA
PaCA-2 cells
Cellular migration and invasion events can be triggered by
a number of molecular signals, such as chemoattractants
and mechanical forces, which are sensed by receptors
on the cell surface or within cells to lead to a migratory
response [31].
The extracellular form of ANXA1 has been described to
play a role in cancer cell invasion and metastasis. Although
the protein does not possess classical signal sequences to
Figure 1 (See legend on next page.)
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Figure 1 Expression and localization of ANXA1 in human PC cells. A, Total ANXA1 expression in MIA PaCa-2, PANC-1, BxPC-3 and CAPAN-2
cells was analyzed by Western blot with anti-ANXA1 antibody. Δ represents ANXA1 fold change by densitometry. B, Cultured human MIA PaCa-2,
PANC-1, BxPC-3 and CAPAN-2 cells fixed and labelled with fluorescent antibody against E-cadherin and vimentin (green). C, D, Quantitative analysis of
E-cadherin and vimentin protein expression in MIA PaCa-2, PANC-1, BxPC-3 and CAPAN-2 cells. Histograms represent the percentage of E-cadherin and
vimentin positive cells on total DAPI positive nuclei. Results are mean ± standard deviation from three independent experiments, where at least 100
nuclei per cell line were counted. E, Immunofluorescence analysis to detect FAK (panels a, d), ANXA1 (panels b, e, h, m), and F-actin (panels g, l) in MIA
PaCa-2 and PANC-1. Nuclei were stained with DAPI. The merged image shows overlapping localization of the proteins (panels c, f, I, n). Magnification
63×. The data are representative of 5 experiments with similar results. Bar = 10 μm.
Figure 2 Effects of ANXA1 knockdown on migration and invasiveness rate of MIA PaCa-2 and PANC-1 cells. Western blot using an
anti-ANXA1 antibody on protein extracts from MIA PaCa-2 (panel A) or PANC-1 cells (panel D) treated or not with siRNAs direct against ANXA1
(siANXA1). Δ represents ANXA1 fold change normalized to control levels by densitometry. Protein normalization was performed on tubulin levels.
B, Results of wound-healing assay on MIA PaCa-2 (panel B) or PANC-1 cells (panel E) transfected with siANXA1s or scrambled siRNAs. Statistical
significance was calculated using unpaired t-test between control and ANXA1 knock-down cells, **p < 0.01 vs untreated control. The data are
representative of 5 independent experiments ± SEM. Invasiveness rate of MIA PaCa-2 (panel C) or PANC-1 cells (panel F). In invasion assays a total
of 90,000 cells were transfected or not with siANXA1s (5nM) or scrambled siRNAs (5nM) for 72 h and plated as described in Methods section.
Invasiveness rate was founded out by counting stained cells on the lower surface of the filters. Data represent mean cell counts of 12 separate
fields per well ± SEM of 5 experiments. Statistical significance was calculated using unpaired t-test between control and ANXA1 knock-down cells
**p < 0.01 vs serum free (SF) control; ***p < 0.001 vs SF control; ###p < 0.001 vs control.
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truncated forms are often observed in extracellular envi-
ronments. Moreover, it appears that proteolytic cleavage
of ANXA1 is required for protein secretion, because
the majority of ANXA1 released from neutrophils is N-
terminally cleaved [32-38]. Based on this information,
our characterization experiments continued with the
analysis by Western blot of ANXA1 expression in sub-
cellular compartments of MIA PaCa-2 cells. In particu-
lar, we obtained membrane, cytosol and nuclear protein
extracts as described in Methods section. The ANXA1
membrane expression was detected by both fractioned
protein extracts and EDTA wash, with which we obtained
the proteins that bind plasma membrane through calcium.
In MIA PaCa-2 extracts, we found both, full length
(37 kDa) and cleaved (33 kDa) forms of ANXA1 protein
at plasma membrane and in the cytosol but not in the
nucleus where only the 37 kDa ANXA1 form was
expressed. Conversely, PANC-1 didn’t show the ANXA1
cleaved form and the protein expression in sub-cellular
compartments was characterized by a small amount onto
membrane and in the nucleus, if compared with MIA
PaCa-2 cells.
Both full length (37 kDa) and cleaved (33 kDa) forms
of ANXA1 were also observed in MIA PaCa-2 superna-
tants, whereas no protein secretion was observed in the
PANC-1 supernatants (Figure 3).
Expression and activation of FPRs in MIA PaCa-2 and
PANC-1 cells
Cancerous cell capability to migrate and invade tissues is
a decisive aspect of cancer progression and entails the
coordination of several cellular events, such as cytoskel-
etal reorganization, dynamic cell-matrix adhesion and
remodelling [30].
Regulatory action on cell surface by extracellular ANXA1
is reported to be mediated by signalling through FPRs
[12-13; 20,21] that are supposed to regulate cell migration
by actin polymerization.
In order to verify the role of ANXA1-FPR interaction in
MIA PaCa-2 and PANC-1 cell migration and invasiveness,Figure 3 Expression and localization of cleaved and secreted form of
were obtained as described in Methods section. Total (T), membrane (M), E
expression in protein extracts from MIA PaCa-2 and PANC-1 was examined
normalized on tubulin levels. The data are representative of 5 experimentswe first assessed FPR expression in these cell lines by cyto-
fluorimetric analysis (Figure 4A): we found that FPR-1 and
FPR-2 were expressed in both cell lines. These findings
were confirmed by qualitative PCR (Figure 4B).
It is known that the interaction between ANXA1 and
FPRs causes a series of cellular responses, such as the
ERK phosphorylation and the increase of intracellular
[Ca2+] concentration. The N-terminal mimetic peptide
of ANXA1, Ac2-26, can activate all three human FPRs,
promoting calcium fluxes, and cell locomotion. To de-
termine whether ligand binding to FPRs induces similar
signal transduction in MIA PaCa-2 and PANC-1, we
examined the stimulated release of calcium from intracel-
lular stores. Cells were incubated in Ca2+ free medium
and loaded with the fluorescent calcium indicator FURA-
2 AM before stimulation with Ac2-26 (1 μM) or the
natural FPR agonist fMLP (50 nM) together or not with
the FPR pharmacological antagonist Boc-1 (10 μM) that is
able to antagonize all three human FPR isoforms. The
spectrofluorimetric assay (Figure 4, panels C and D) shows
that fMLP and peptide Ac2-26 were able to increase the
mobilization of intracellular Ca2+ in both MIA PaCa-2
and PANC-1 cells. In fact, no significant differences be-
tween ionomycin (used as reference compound) and
fMLP or Ac2-26 were observed. The effects of fMLP and
Ac2-26 peptides were inhibited by the pharmacological
pan-antagonist Boc-1 in both cell lines.
Effects of extracellular ANXA1 on MIA PaCa-2 and PANC-1
cells
To determine if ANXA1 influences cell migration acting
through FPRs, we performed a wound-healing migration
assay on cellular monolayer in both the analyzed cell
lines.
For MIA PaCa-2, results in Figure 5A showed an
increase in migration speed of cells treated with Ac2-26
(1 μM) or fMLP (50 nM) compared to control cells. The
FPR pan-antagonist Boc-1 (10 μM) significantly inhibited
basal and stimulated migration. Interestingly, an ANXA1
blocking antibody was able to reduce in a significant
manner MIA PaCa-2 cell migration (Figure 5B).ANXA1 from MIA PaCa-2 and PANC-1 cells. Cellular compartments
DTA Wash (EW), cytosolic (C), nuclear (N) and supernatant (S) ANXA1
by Western blot with anti-ANXA1 antibody. The protein bands were
with similar results.
Figure 4 (See legend on next page.)
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Figure 4 FPR-1 and 2 expression and activation in MIA PaCa-2 and PANC-1 cells. A, Cell surface expression of FPR-1 and FPR-2 in MIA
PaCa-2 and PANC-1 cells was analyzed by flow cytometry. The violet areas in the plots are relative to secondary antibody alone. FPR-1 and FPR-2
signals are showed with green bends. B, Expression of FPR-1 and FPR-2 in MIA PaCa-2 and PANC-1 cells analyzed by PCR. Effects of fMLP (50 nM),
Ac-2-26 (1 μM) and FPR pan-antagonist Boc-1 (10 μM) on the FPR-induced rise in intracellular Ca2+ in MIA PaCa-2 (panel C) or PANC-1 cells (panel
D). Cells were treated as described in Methods section. The histograms show the fluorescence ratio calculated as F340/F380 nm in absence of
extracellular Ca2+. Control represents ionomycin-stimulated cells. Data are means ± SEM (n = 5).
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cussed; this protein may have specific functions in differ-
ent tumoral models. For example, in gastric and colon
carcinomas ANXA1 has a pro-invasive role through its
interaction with FPRs [15,21].
When treated with Ac2-26 (1 μM) and fMLP (50 nM),
MIA PaCa-2 cells showed an increased invasion speed
through coating of matrigel. Again, Boc-1 antagonist
(10 μM, Figure 5C) reduced in a significant manner
MIA PaCa-2 stimulated cell invasion. An ANXA1 block-
ing antibody was also able to inhibit basal cell invasion
(Figure 5D).
At the same time, we used PANC-1 cell line as basis
for comparison, as these cells did not show either the
ANXA1 cleaved form or the externalized one. Similarly
for MIA PaCa-2, results of the wound-healing migration
assay on cellular monolayer showed an increase in
migration speed of the cells treated with Ac2-26 (1 μM)
or fMLP (50 nM) when compared to control cells and a
reverted effect in cells treated with the pan-antagonist
Boc-1 (10 μM) (Figure 5E). Interestingly, ANXA1 block-
ing antibody had no effects on PANC-1 cell motility
(Figure 5F). In order to verify whether the absence of
extracellular ANXA1 in PANC-1 cell line was also
implied in a different invasiveness rate, we performed a
matrigel invasion assay. When treated with Ac2-26
(1 μM) and fMLP (50 nM), PANC-1 cells showed a large
invasion speed through coating of matrigel. In both of
cases, experimental points were compared with non
treated control or with Boc-1 antagonist (10 μM) treated
cells (Figure 5G). ANXA1 blocking antibody had no
effects on PANC-1 invasiveness (Figure 5H).
Effects of MIA PaCa-2 supernatants on PANC-1 cell migration
Our data suggest a double role of ANXA1 in PC cell
motility. In one way the protein acts in the intracellular
environment thanks to its involvement in cytoskeleton
reorganization, as confirmed by immunofluorescence assay
showed in Figure 1E. In another one, ANXA1 externalized
form appears to bind FPRs and trigger some molecular
pathways that lead to cell migration and invasion. Based on
these findings, we focused on the appearance of a 33 kDa
form only in MIA PaCa-2 cells, both in total (Figure 1A)
and supernatant extracts (Figure 3). Therefore, in order to
detect possible ANXA1 fragments released from the cells a
multi-step fractionation of MIA PaCa-2 supernatants wasperformed. Obtained samples were analyzed by LC-HRMS/
MS as described in Methods section. A peptide showing a
molecular weight of 2744.324 was detected; on the basis of
its molecular weight and of the CID induced fragmentation
spectrum (Figure 6A), this peptide was identified as the
fragment 4-26 of ANXA1.
Furthermore, we considered the higher migratory and
invasive rate of MIA PaCa-2 compared with PANC-1
cells [26]. In order to confirm that the secreted forms of
ANXA1 protein were able to induce PC cell migration
and invasion in autocrine and paracrine manner, we per-
formed further experiments adding MIA PaCa-2 super-
natants to PANC-1 cells and viceversa. As shown in
Figure 6B, MIA PaCa-2 supernatants containing all the
secreted forms of ANXA1 protein (37 kDa, 33 kDa and
3 kDa) significantly increased PANC-1 cell migration rate.
Conversely, the administration of PANC-1 supernatants
on MIA PaCa-2 cells had no effects on migration speed
of the latter ones. Moreover, the administration of MIA
PaCa-2 conditioned supernatant containing ANXA1
blocking antibody on PANC-1 cells did not increase the
migration rate of these cells.
Discussion
The role of ANXA1 in tumours is paradoxical since
ANXA1 appears to behave either as a tumour suppressor
or an oncogenic gene. As the mechanism of ANXA1 in
cancer progression has not been still completely clarified,
more studies are required to investigate the detailed action
mechanisms of this protein in tumours. Accumulated
evidences have indicated that ANXA1 deregulation and
sub-cellular localization are involved in the development,
invasion, metastasis and drug resistance of a variety of
cancers suggesting a tissue type-specific role for ANXA1
in tumour advancing [9]. In particular, concerning cellular
motility, ANXA1 actions are exerted extracellularly via
FPRs in autocrine/paracrine manner, but also in the intra-
cellular environment where it contributes to the dynamic
reorganization of the actin cytoskeleton [11].
It has been shown that ANXA1 over-expression in the
tissues from patients with PC is correlated with poor dif-
ferentiation and prognosis and seems to be associated
with malignant transformation and cancer progression
[39-42].
In the present paper, we report that ANXA1 could
have a role in PC cell migration and invasiveness and
Figure 5 (See legend on next page.)
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Figure 5 Wound-healing and matrigel invasion assay on MIA PaCa-2 and PANC-1 cells.Wound-healing assay on MIA PaCa-2 (panel A) or PANC-1
cells (panel E) treated or not with fMLP (50nM), Ac2-26 (1 μM), Boc-1 (10 μM), fMLP + Boc-1 or Ac2-26 + Boc-1; Statistical significance was calculated using
two way ANOVA,* p < 0.05, **p < 0.01, ***p < 0.001 vs untreated control; ##p < 0.01 and §§p < 0.01 vs respective controls. Wound-healing assay on MIA
PaCa-2 (panel B) or PANC-1 cells (panel F) treated or not with ANXA1 blocking antibody (AbANXA1) or scrambled rabbit IgG (IgG R); Statistical significance
was calculated using unpaired t-test between control and treated cells, ***p < 0.001 vs untreated control. All wound-healing data are representative of 5
experiments ± SEM. Invasiveness rate of MIA PaCa-2 (panel C) or PANC-1 cells (panel G) treated or not with fMLP (50 nM), Ac2-26 (1 μM), Boc-1
(10 μM), fMLP + Boc-1 or Ac2-26 + Boc-1; Statistical significance was calculated using two way ANOVA, ***p < 0.001 vs untreated control; ###p < 0.001
and §§§p < 0.001 vs respective controls. Invasiveness rate of MIA PaCa-2 (panel D) or PANC-1 cells (panel H) treated or not with AbANXA1 or IgG R;
Statistical significance was calculated using unpaired t-test between control and treated cells, ***p < 0.001 vs untreated control. Invasiveness rates were
measured as described in Methods section. Data represent mean cell counts of 12 separate fields per well ± SEM of 5 independent experiments.
Figure 6 Analysis of the secreted forms of ANXA1 and of their effects on PC cell motility. A, LC-HRMS/MS spectrum, peaks refer to all the
discovered peptide fragments. The data are representative of 5 experiments with similar results. B, Effects of MIA PaCa-2 supernatants on PANC-1
cells and viceversa in a wound-healing assay. Statistical significance was calculated using unpaired t-test between control and treated cells,
***p < 0.001. Data are means ± SEM (n = 5).
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cells.
We first analyzed ANXA1 expression in MIA PaCa-2,
PANC-1, BxPC-3 and CAPAN-2 PC cell lines and we
found that all of them expressed high levels of ANXA1.
Moreover, all analyzed PC cell lines showed at least
two different phenotypes: a less aggressive epithelial-like
and a more aggressive mesenchymal-like. In the latter,
ANXA1 was mainly localized in the regions involved in
cellular motility, suggesting an intracellular role for the
protein in the processes of cell migration/invasion.
Given the less aggressive phenotype of CAPAN-2 and
BxPC-3 cells, we chose to use only MIA PaCa-2 and
PANC-1 cells that present more marked mesenchymal
features. In particular, among the other PC cell lines,
MIA PaCa-2 cells are commonly used to induce tumour
xenografts in nude mice because of their strong capabil-
ity to develop not only the largest tumoral mass but also
metastasis [26].
Actually, the inhibition by siRNAs of ANXA1 expres-
sion in both MIA PaCa-2 and PANC-1 cells induced a
significant decrease of the migration rate and markedly
suppressed the invasiveness of these cells, confirming
that intracellular ANXA1 is involved in PC cell migra-
tion/invasion.
ANXA1 has been shown to differently localize to the
cellular compartments of various cell types including
leukocytes, endothelial cells, lung epithelial cells and
synoviocytes where it is thought to be important in bio-
logical functions [43-47]. Moreover, recent studies have
shown that, in PC tissues, localization of ANXA1 was
different in cytoplasm and membrane of tumour cells,
indicating that the function of ANXA1 may vary among
its differential localization.
We found that both MIA PaCa-2 and PANC-1 cells
exhibit membrane and nuclear ANXA1 expression.
ANXA1 membrane translocation has been reported to
be strictly related to both membrane trafficking and
secretion of the protein in extracellular environments
and to be leaded by post-translational modifications [32].
Concerning the exact physiological functions of nuclear-
translocated ANXA1 protein, accumulated evidence like
in oral squamous cell carcinoma, gastric carcinoma and
oesophageal squamous cell carcinoma, indicate that
ANXA1 nuclear expression correlates with advanced
disease and cancer dissemination. However, the mecha-
nisms underlying ANXA1 nuclear translocation remain
unknown [48-50].
We also found that MIA PaCa-2 cells exhibit increased
extracellular ANXA1, so that we have hypothesized a role
for the secreted protein in regulating PC cell migration/
invasion through the interaction with FPRs.
FPRs are expressed in several cellular populations and
bind a variety of exogenous and endogenous ligands thatelicit differential biological responses [16]. ANXA1 and
its N-terminal mimetic peptide, Ac2-26, are endogenous
FPR ligands. Flow cytometry and PCR analyses showed
that MIA PaCa-2 and PANC-1 cells express FPR-1 and
FPR-2. Moreover, experiments on the mobilization of
intracellular calcium have confirmed the activity of the
FPRs in these cell lines, following stimulation with the
Ac2-26 peptide. We found no receptor activation in
presence of Boc-1, a molecule that at a dose of 10 μM
can be considered as able to block all the three receptor
isoforms [16].
Exogenous administration of Ac2-26 was also able to
increase migration speed and invasiveness of cells through
coating of matrigel, compared to relative controls. The
specificity of Ac2-26-induced effects on wound closure
and invasiveness through the FPRs was confirmed by
administration of the FPR pan-antagonist Boc-1. The
same results were obtained with ANXA1 blocking anti-
body, able to reduce PC cell motility in MIA PaCa-2 cells.
Our results are consistent with the observed role of
ANXA1 in head neck squamous cancers where the
protein over-expression was associated with increased
tumour invasiveness and metastasis and in SK-CO15
intestinal epithelial cells where ANXA1 regulated cellular
invasive behaviour acting through FPRs [51,21].
Differently from MIA PaCa-2, no secreted forms of
ANXA1 protein were observed in protein supernatant
extracts from PANC-1 cells, consequently, we reasoned
on the role of the extracellular protein in PC cell line
migration and invasiveness. Results of a wound-healing
migration assay on PANC-1 cells showed an increase in
migration and invasiveness rate of cells treated with
Ac2-26: these findings are consistent with the expression
of FPR-1 and FPR-2 that we found in these cells. How-
ever, we showed that ANXA1 blocking antibody had no
effects on PANC-1 cell motility.
We also report the presence of the full-length form
(37 kDa) accompanied by the appearance of the 33 kDa
cleavage product of ANXA1 in several cellular compart-
ments of MIA PaCa-2 cells. Furthermore, these two forms
are secreted outside the cells, since they appeared in cellu-
lar supernatants. LC-HRMS/MS, used to characterize
secreted forms of ANXA1, showed a peptide with molecu-
lar weight of 2744.324 demonstrating, for the first time,
the presence of the fragment 4-26 of ANXA1 in the extra-
cellular environments.
In PC there is an abnormally high expression of a num-
ber of important tyrosine kinase growth factors and recep-
tors, like the Epidermal Growth Factor (EGF) family, which
may contribute to the neoplasia growth by autocrine and
paracrine effects [40,41]. Immunohistochemistry studies
showed that EGF Receptor (EGFR) over-expression posi-
tively correlates with advanced tumour staging and lymph
node metastasis [42]. ANXA1 is a substrate protein of
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EGFR pathway could promote ANXA1 up-regulation and
post-transductional modifications, which might be associ-
ated with its membrane translocation and secretion [52].
ANXA1 cleavage and secretion could be also mediated
by several proteinases [53]: differential expression or activ-
ity of these enzymes could explain the lack of both
ANXA1 cleavage and secretion in PANC-1 cells. However,
further studies will be needed to address this point.
As previously reported, MIA PaCa-2 have a more inva-
sive behaviour than PANC-1 cells [54,55] and we suppose
that these differences could be due to the presence of
secreted forms of ANXA1 protein. The addition of MIA
PaCa-2 supernatant to PANC-1 cells significantly stimu-
lated PANC-1 migration rate. Conversely, PANC-1 super-
natant administration on MIA PaCa-2 cells had no effects
on cell motility, confirming that the secreted forms of
ANXA1 protein may be able to induce PC cell migration
and invasion.
The therapeutic properties of ANXA1 on wound clos-
ure are well known in other tissues and could be due to
the autocrine and paracrine anti-inflammatory effects of
its N-terminus peptide, Ac2-26, that is released from the
full length protein through regulated proteolysis [56]. It
has recently shown that both the full length protein and
the Ac2-26 peptide promote cell motility in intestinal
epithelial cells through FPRs [57]. Our studies are consist-
ent with these findings and could explain the biological
effects of ANXA1 and its cleavage products on the ability
of MIA PaCa-2 cells to have a more invasive behaviour.
Conclusions
In summary, our data suggest a role for intracellular and
extracellular ANXA1 in stimulating PC cell migration and
invasion. However, future studies on PC patients will be
needed to determine whether ANXA1 could represent a
potential diagnostic, prognostic or predictive biomarker
by correlating the progression and/or metastatic rate of
the tumour to the protein expression.
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